The year 2015 saw the approval of six new targeted therapies for the treatment of non-small-cell lung cancer (NSCLC). This analysis discusses recently approved as well as late-stage compounds and examines how different drug classes will affect the NSCLC market.
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
科研狗
你嵙这个期刊没买
zzc7
小太阳在营业
null
挖掘机
蓝莓橘子酱
云九卿
寻道图强
pluto
热心市民小红花
小米
GingerF
Yong
互助
ffrrss
wanci
smottom
宋木
皖公网安备34019202002308
